Troubles du Sommeil : 4 Vérités choquantes
dont votre médecin ne vous a jamais parlé

Référence scientifiques

Cette présentation a été élaborée à partir des données émanant des instituts suivants :

1) Kumari M , Badrick E , Ferrie J , Perski A , Marmot M , Chandola T 2009 Self-reported sleep duration and sleep disturbance are independently associated with cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 94:4801–4809

2) C. Castro-Diehl, A.V. Diez Roux, S. Redline, T. Seeman, S.E. Shrager, S. Shea
Association of sleep duration and quality with alterations in the hypothalamic–pituitary–adrenocortical axis: the multi-ethnic study of atherosclerosis (MESA) J. Clin. Endocrinol. Metab., 100 (2015), pp. 3149-3158

3) Vgontzas, A. N., Tsigos, C., Bixler, E. O., Stratakis, C. A., Zachman, K., Kales, A., et al. (1998). Chronic insomnia and activity of the stress system: A preliminary study. Journal of Psychosomatic Research, 45, 21–31.

4) Collier J. Big pharma and the UK Government
The Lancet, Volume 367, No. 9505, p97–98, 14 January 2006

5) Cordi MJ, Schlarb AA, Rasch B. Deepening sleep by hypnotic suggestion. SLEEP 2014;37(6):1143-1152.

6) Billioti de Gage S Moride Y Ducruet T Kurth T Verdoux H Tournier M Pariente A Bégaud B (2014) Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 9 ;349:g5205.

7) Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert opinion on drug safety. 2015:1–15.

8) Zhong G, Wang Y, Zhang Y, Zhao Y. 2014. Association between benzodiazepine use and dementia: a meta-analysis. PLoS One 10(5): e0127836. DOI:10.1371/journal. pone.0127836

9) TAKADA, M.; FUJIMOTO, M.; HOSOMI, K. Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases. International journal of Medical Sciences, v. 13, n. 11, p. 825–834, 2016.

10) Baron KG, Reid KJ, Zee PC. Exercise to improve sleep in insomnia: exploration of the bidirectional effects. J Clin Sleep Med. 2013;9:819–24.

11) Abell, J. G., Shipley, M. J., Ferrie, J. E., Kivimäki, M., & Kumari, M. (2016). Recurrent short sleep, chronic insomnia symptoms and salivary cortisol: A 10-year follow-up in the Whitehall II study. Psychoneuroendocrinology, 68, 91–99.

12) Rodenbeck AHuether GRuther EHajak G Interactions between evening and nocturnal cortisol secretion and sleep parameters in patients with severe chronic primary insomnia. Neurosci Lett 2002;324159- 163

13) Vgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., et al. (2001). Chronic insomnia is associated with nyctohemeral activation of the hypothalamic–pituitary–adrenal axis: Clinical implications. The Journal of Clinical Endocrinology & Metabolism, 86, 3787–3794.

14) Xia L, Chen GH, Li ZH, Jiang S, Shen J. Alterations in hypothalamus-pituitary-adrenal/thyroid axes and gonadotropin-releasing hormone in the patients with primary insomnia: a clinical research. PLoS ONE. 2013;8(8):e71065.

15) Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res. 2016;5:918.

16) Simon Beaulieu-Bonneau, Mélanie LeBlanc, Chantal Mérette, Yves Dauvilliers, Charles M. Morin; Family History of Insomnia in a Population-Based Sample, Sleep, Volume 30, Issue 12, 1 December 2007, Pages 1739–1745

17) Dauvilliers Y, Morin C, Cervena K, et al. Family studies in insomnia. J Psychosom Res 2005;58:271-8.

18) Allaert FA, Urbinelli R. Sociodemographic profile of insomniac patients
across national surveys. CNS Drugs 2004;18(Suppl 1):3–7.

19) OHAYON M.M. - Prévalence et comorbidité des troubles du sommeil dans la population générale. La revue du Praticien. 2007, 57, 1521-1528.

20) ] Quera-Salva MA, Orluc A, Goldenberg F, Guilleminault C. Insomnia and use of hypnotics: study of a French population. Sleep 1991;14:386–91.

21) Sachar, E. J., Fishman, J. R., & Mason, J. W. (1965). Influence of the hypnotic trance on plasma 17-hydroxycorticosteroid concentration. Psychosomatic Medicine, 27(4), 330-341.

22) SACHAR EJ, COBB JC, SHOR RE. Plasma Cortisol Changes During Hypnotic Trance Relation to Depth of Hypnosis. Arch Gen Psychiatry. 1966;14(5):482–490. doi:10.1001/archpsyc.1966.01730110034005

23) ZACHARIAE, R., BJERRING, P., ZACHARIAE, C., ARENDT-NIELSEN, L., NIELSEN, T., ELDRUP, E., LARSEN, C. S. and GOTLIEBSEN, K. (1991), Monocyte Chemotactic Activity in Sera after Hypnotically Induced Emotional States. Scandinavian Journal of Immunology, 34: 71–79. doi:10.1111/j.1365-3083.1991.tb01522.x

24) Kendrick, C., Johnson, A. K., Sliwinski, J., Patterson, V., Fisher, W. I., Elkins, G. R., & Carpenter, J. S. (2015). Hypnotic relaxation therapy for reduction of hot flashes in postmenopausal women: Examination of cortisol as a potential mediator. International Journal of Clinical and Experimental Hypnosis, 63(1), 76-91.

25) Varga K, Kekecs Z. Oxytocin and cortisol in the hypnotic interaciton. International Journal of Clinical and Experimental Hypnosis. 2014;62:84–110.

26) Schlarb, A.A., 2005. Verhaltenstherapie und Hypnotherapie bei primärer Insomnie. Eberhard-Karls Universität Tübingen (June 20)

27) Stanton, Harry E. (1999). Hypnotic Relaxation and Insomnia: A Simple Solution? Sleep and Hypnosis, Vol 1(1), 64-67.